NNP
IMGN

Nachman Norwood & Parrott’s Immunogen Inc IMGN Stock Holding History

Nachman Norwood & Parrott’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,122
Closed -$4K – 1114
2020
Q3 		$4K Buy
+1,122
New +$4.53K ﹤0.01% 1019

Other funds holding IMGN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nachman Norwood & Parrott's IMGN Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of Immunogen Inc (IMGN) in Q4 2020, closing a stake of 1,122 shares — an estimated $4K sold.

Nachman Norwood & Parrott first reported a position in IMGN in Q3 2020 and held it in 1 quarter. The position peaked at $4K in Q3 2020. 211 funds tracked by Wall St. Rank hold IMGN as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining Immunogen Inc position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 1,122 Immunogen Inc shares in Q4 2020, an estimated $4K.
  • Nachman Norwood & Parrott first reported a position in Immunogen Inc in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's Immunogen Inc position peaked at $4K in Q3 2020.
  • 211 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.